CoChat
Sign Up
Cited by 104Ovarian function and disordersGut microbiota and healthEndometriosis Research and Treatment

Intersection of Polycystic Ovary Syndrome and the Gut Microbiome

Open access
Rizk, Maryan G, Thackray, Varykina G·2021·Journal of the Endocrine Society
DOI 10.1210/jendso/bvaa177PMC PMC7757431
Open this paper in CoChat — free accountOpen PDF

Abstract

The etiology of polycystic ovary syndrome (PCOS) remains unclear, although studies indicate that both genetic and environmental factors contribute to the syndrome. In 2012, Tremellen and Pearce proposed the idea that dysbiosis of the intestinal (gut) microbiome is a causative factor of metabolic and reproductive manifestations of PCOS. In the past 5 years, studies in both humans and rodent models have demonstrated that changes in the taxonomic composition of gut bacteria are associated with PCOS. Studies have also clearly shown that these changes in gut microbiota are associated with PCOS as opposed to obesity, since these changes are observed in women with PCOS that are both of a normal weight or obese, as well as in adolescent girls with PCOS and obesity compared with body mass index- and age-matched females without the disorder. Additionally, studies in both women with PCOS and rodent models of PCOS demonstrated that hyperandrogenism is associated with gut microbial dysbiosis, indicating that androgens may modulate the gut microbial community in females. One study reported that the fecal microbiome transplantation of stool from women with PCOS or exposure to certain bacteria resulted in a PCOS-like phenotype in mice, while other studies showed that exposure to a healthy gut microbiome, pre/probiotics, or specific gut metabolites resulted in protection from developing PCOS-like traits in mice. Altogether, these results suggest that dysbiosis of the gut microbiome may be sufficient to develop PCOS-like symptoms and that modulation of the gut microbiome may be a potential therapeutic target for PCOS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvaa177

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lifestyle-induced changes in the gastrointestinal tract microbiome are a significant factor in the etiology of PCOS.

    “Lifestyle-induced changes in the gastrointestinal tract microbiome are another significant factor in the etiology of PCOS [52,53].”

    From Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment (2022) · cites this paper as [52]

    The Summary (page not provided) reports an association between gut-microbiome changes and PCOS and describes dysbiosis as a possible driver, not an established significant cause. The paper also does not establish that the PCOS-associated changes are lifestyle-induced; its Caveats and future directions section says further work is needed to distinguish effects of diet from changes related to PCOS. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 82

  1. [1]Rao P, Bhide P. Controversies in the diagnosis of polycystic ovary syndrome. Ther Adv Reprod Health. 2020; 14: 1– 11. PMC7328349 32656532
  2. [2]Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018; 15(11): 1– 13. PMC6266413 30463276
  3. [4]Hull MG. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol. 1987; 1(3): 235– 245. 3140583
  4. [5]Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6): 2745– 2749. 15181052
  5. [6]Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 2. Endocr Pract. 2015; 21(12): 1415– 1426. 26642102
  6. [7]Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015; 21(5): 575– 592. 26117684
  7. [8]Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007; 66(4): 513– 517. 17371468
  8. [10]Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome part 1. Endocr Pract. 2015; 21(11): 1291– 1300. 26509855
  9. [11]Azziz R, Carmina E, Chen Z, et al Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2): 1– 18. 27510637
  10. [12]Churchill SJ, Wang ET, Pisarska MD. Metabolic consequences of polycystic ovary syndrome. Minerva Ginecol. 2015; 67(6): 545– 555. 26372304
  11. [13]Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014; 20(26): 8351– 8363. 25024594 PMC4093689
  12. [15]Barko PC, McMichael MA, Swanson KS, Williams DA. The gastrointestinal microbiome: a review. J Vet Intern Med. 2018; 32(1): 9– 25. 29171095 PMC5787212
  13. [16]Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2019; 216(1): 20– 40. 30322864 PMC6314516
  14. [22]Liu R, Zhang C, Shi Y, et al Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. 2017; 8: 1– 12. 28293234 PMC5328957
  15. [23]Qi X, Yun C, Sun L, et al Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019; 25(8): 1225– 1233. 31332392 PMC7376369
  16. [24]Zeng B, Lai Z, Sun L, et al Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study. Res Microbiol. 2019; 170(1): 43– 52. 30292647
  17. [25]Zhang J, Sun Z, Jiang S, et al Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain Axis. mSystems. 2019; 4(2): 1– 16. PMC6469956 31020040
  18. [27]Liang Y, Ming Q, Liang J, Zhang Y, Zhang H, Shen T. Gut microbiota dysbiosis in polycystic ovary syndrome: association with obesity – a preliminary report. Can J Physiol Pharmacol. 2020; 98(11): 803– 809. 32150694
  19. [28]Torres PJ, Siakowska M, Banaszewska B, et al Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018; 103(4): 1502– 1511. 29370410 PMC6276580
  20. [29]Arroyo P, Ho BS, Sau L, Kelley ST, Thackray VG. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. Plos One. 2019; 14(9): 1– 17. PMC6768472 31568518
  21. [31]Torres PJ, Ho BS, Arroyo P, et al Exposure to a healthy gut microbiome protects against reproductive and metabolic dysregulation in a PCOS mouse model. Endocrinology. 2019; 160(5): 1193– 1204. 30924862 PMC6482036
  22. [32]Zheng Y, Yu J, Liang C, Li S, Wen X, Li Y. Characterization on gut microbiome of PCOS rats and its further design by shifts in high-fat diet and dihydrotestosterone induction in PCOS rats. Bioprocess Biosyst Eng. 2020. 10.1007/s00449-020-02320-w 32157446 · DOI
  23. [33]Haudum C, Lindheim L, Ascani A, et al Impact of short-term isoflavone intervention in polycystic ovary syndrome (PCOS) patients on microbiota composition and metagenomics. Nutrients. 2020; 12(6): 1– 22. PMC7656308 32492805
  24. [34]Eyupoglu ND, Ergunay K, Acikgoz A, Akyon Y, Yilmaz E, Yildiz BO. Gut microbiota and oral contraceptive use in overweight and obese patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2020: 1– 9. 32860695
  25. [35]Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19– 25. 14711538
  26. [36]Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41– 47. 14688154
  27. [37]Jobira B, Frank DN, Pyle L, et al Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. J Clin Endocrinol Metab. 2020; 105(6): 1– 11. PMC7147870 31970418
  28. [38]Peña AS, Witchel SF, Hoeger KM, et al Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020; 18(1): 1– 16. 32204714 PMC7092491
  29. [39]Tilman D, Reich PB, Knops J, Wedin D, Mielke T, Lehman C. Diversity and productivity in a long-term grassland experiment. Science. 2001; 294(5543): 843– 845. 11679667
  30. [40]Kowalska-Duplaga K, Gosiewski T, Kapusta P, et al Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease. Sci Rep. 2019; 9(1): 18880. 31827191 PMC6906406
  31. [41]Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat Commun. 2017; 8(1): 1– 10. 29209090 PMC5716994
  32. [42]Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016; 7: 1– 12. 27065999 PMC4815357
  33. [43]Menni C, Lin C, Cecelja M, et al Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J. 2018; 39(25): 2390– 2397. 29750272 PMC6030944
  34. [44]Menni C, Zhu J, Le Roy CI, et al Serum metabolites reflecting gut microbiome alpha diversity predict type 2 diabetes. Gut Microbes. 2020; 11(6): 1632– 1642. 32576065 PMC7524143
  35. [46]Stener-Victorin E, Padmanabhan V, Walters KA, et al Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr Rev. 2020; 41(4): 538– 576. PMC7279705 32310267
  36. [47]Torres PJ, Skarra DV, Ho BS, et al Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. BMC Microbiol. 2019; 19(1): 1– 15. 30871463 PMC6419356
  37. [48]He Y, Wang Q, Li X, et al Lactic acid bacteria alleviate polycystic ovarian syndrome by regulating sex hormone related gut microbiota. Food Funct. 2020; 11(6): 5192– 5204. 32441726
  38. [50]Zhang F, Ma T, Cui P, et al Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of diane-35, probiotics, and berberine. Front Microbiol. 2019; 10: 1– 14. 30800111 PMC6375883
  39. [51]Allaband C, McDonald D, Vázquez-Baeza Y, et al Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians. Clin Gastroenterol Hepatol. 2019; 17(2): 218– 230. 30240894 PMC6391518
  40. [52]Zhu S, Zhang B, Jiang X, et al Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019; 111(1): 168– 177. 30611404
  41. [53]Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981– 1030. 23065822 PMC5393155
  42. [54]Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004; 35(2): 103– 108. 15010188
  43. [55]Mannerås L, Cajander S, Holmäng A, et al A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148(8): 3781– 3791. 17495003
  44. [56]van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology. 2012; 153(6): 2861– 2869. 22334715
  45. [57]Park JH, Choi TS. Polycystic ovary syndrome (PCOS)-like phenotypes in the d-galactose-induced aging mouse model. Biochem Biophys Res Commun. 2012; 427(4): 701– 704. 23022527
  46. [58]Kauffman AS, Thackray VG, Ryan GE, et al A novel letrozole model recapitulates both the reproductive and metabolic phenotypes of polycystic ovary syndrome in female mice. Biol Reprod. 2015; 93(3): 1– 12. PMC4710190 26203175
  47. [59]Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ. Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe. 2017; 22(6): 757– 765.e3. 29199098 PMC5730482
  48. [60]Park JC, Im SH. Of men in mice: the development and application of a humanized gnotobiotic mouse model for microbiome therapeutics. Exp Mol Med. 2020; 52(9): 1383– 1396. 32908211 PMC8080820
  49. [61]Thackray VG. Sex, microbes, and polycystic ovary syndrome. Trends Endocrinol Metab. 2019; 30(1): 54– 65. 30503354 PMC6309599
  50. [62]Vom Steeg LG, Klein SL. Sex steroids mediate bidirectional interactions between hosts and microbes. Horm Behav. 2017; 88: 45– 51. 27816626 PMC6530912
  51. [63]Skarra DV, Hernández-Carretero A, Rivera AJ, Anvar AR, Thackray VG. Hyperandrogenemia induced by letrozole treatment of pubertal female mice results in hyperinsulinemia prior to weight gain and insulin resistance. Endocrinology. 2017; 158(9): 2988– 3003. 28911175 PMC5659661
  52. [64]Xue J, Li X, Liu P, et al Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. Endocr J. 2019; 66(10): 859– 870. 31270279
  53. [65]Janse F, Eijkemans MJ, Goverde AJ, et al Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol. 2011; 165(6): 925– 933. 21969522
  54. [66]Deswal R, Yadav A, Dang AS. Sex hormone binding globulin – an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med. 2018; 64(1): 12– 24. 29227165
  55. [67]Zhao Y, Fu L, Li R, et al Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012; 10: 1– 12. 23198915 PMC3599233
  56. [68]Scheiman J, Luber JM, Chavkin TA, et al Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. Nat Med. 2019; 25(7): 1104– 1109. 31235964 PMC7368972
  57. [69]Hove H, Nordgaard-Andersen I, Mortensen PB. Faecal DL-lactate concentration in 100 gastrointestinal patients. Scand J Gastroenterol. 1994; 29(3): 255– 259. 8209186
  58. [70]Gillis CC, Hughes ER, Spiga L, et al Dysbiosis-associated change in host metabolism generates lactate to support salmonella growth. Cell Host Microbe. 2018; 23(1): 54– 64 e56. 29276172 PMC5764812
  59. [71]Eyupoglu ND, Caliskan Guzelce E, Acikgoz A, et al Circulating gut microbiota metabolite trimethylamine N-oxide and oral contraceptive use in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019; 91(6): 810– 815. 31556132
  60. [72]Huang J, Liu L, Chen C, Gao Y. PCOS without hyperandrogenism is associated with higher plasma trimethylamine N-oxide levels. BMC Endocr Disord. 2020; 20(1): 1– 9. 31906930 PMC6945624
  61. [73]Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins (Basel). 2016; 8(11): 1– 11. PMC5127123 27834801
  62. [74]McGlone ER, Bloom SR. Bile acids and the metabolic syndrome. Ann Clin Biochem. 2019; 56(3): 326– 337. 30453753
  63. [75]Li C, Li Y, Gai Z. Bile acids and farnesoid X receptor: novel target for the treatment of diabetic cardiomyopathy. Curr Protein Pept Sci. 2019; 20(10): 976– 983. 31362653
  64. [76]Jia ET, Liu ZY, Pan M, Lu JF, Ge QY. Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases. J Zhejiang Univ Sci B. 2019; 20(10): 781– 792. 31489798 PMC6751489
  65. [77]Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016; 24(1): 41– 50. 27320064
  66. [78]Zhang B, Shen S, Gu T, et al Increased circulating conjugated primary bile acids are associated with hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2019; 189: 171– 175. 30849463
  67. [79]Jia C, Xu H, Xu Y, Xu Y, Shi Q. Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry. Mol Reprod Dev. 2019; 86(3): 292– 297. 30624822
  68. [81]Makishima M, Okamoto AY, Repa JJ, et al Identification of a nuclear receptor for bile acids. Science. 1999; 284(5418): 1362– 1365. 10334992
  69. [82]Parks DJ, Blanchard SG, Bledsoe RK, et al Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999; 284(5418): 1365– 1368. 10334993
  70. [83]Maruyama T, Miyamoto Y, Nakamura T, et al Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002; 298(5): 714– 719. 12419312
  71. [85]Goodwin B, Gauthier KC, Umetani M, et al Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci U S A. 2003; 100(1): 223– 228. 12509506 PMC140933
  72. [86]Studer E, Zhou X, Zhao R, et al Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012; 55(1): 267– 276. 21932398 PMC3245352
  73. [87]Raufman JP, Chen Y, Cheng K, Compadre C, Compadre L, Zimniak P. Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry. Eur J Pharmacol. 2002; 457(2– 3): 77– 84. 12464352
  74. [88]Cariou B, van Harmelen K, Duran-Sandoval D, et al The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006; 281(16): 11039– 11049. 16446356
  75. [90]Shamasbi GS, Dehgan P, Charandabi SM-A, Aliasgarzadeh A, Mirghafourvand M. The effect of resistant dextrin as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized, triple-blind, controlled, clinical trial. Eur J Nutr. 2019; 58(2): 629– 640. 29480399
  76. [91]Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000; 73(6): 1149– 1154. 10856473
  77. [92]Ciçek MN, Bala A, Celik C, Akyürek C. The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Arch Gynecol Obstet. 2003; 268(2): 107– 112. 12768300
  78. [93]Lee BH, Indran IR, Tan HM, et al A dietary medium-chain fatty acid, decanoic acid, inhibits recruitment of Nur77 to the HSD3B2 promoter in vitro and reverses endocrine and metabolic abnormalities in a rat model of polycystic ovary syndrome. Endocrinology. 2016; 157(1): 382– 394. 26465200
  79. [95]Sun L, Xie C, Wang G, et al Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018; 24(12): 1919– 1929. 30397356 PMC6479226
  80. [96]de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017; 40(1): 54– 62. 27999002
  81. [97]Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015; 33: 747– 785. 25706098 PMC4407497
  82. [98]Qi X, Yun C, Liao B, Qiao J, Pang Y. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome. J Endocrinol. 2020; 245(2): 281– 289. 32163914

Cited by

Sorted by citations

Authors
Rizk, M. G., & Thackray, V. G.
Affiliations
University of California San Diego (US)
Corresponding author
Thackray, Varykina G
ORCID
Venue
Journal of the Endocrine Society
Publisher
The Endocrine Society
Published
2020-11-16
Volume
5
Issue
2
Pages
bvaa177-bvaa177
ISSN
2472-1972 (ISSN-L)
DOI
10.1210/jendso/bvaa177
PMC
PMC7757431
OpenAlex
W3103082953
Cited by
104
References
16
Citations by year
2026: 20 · 2025: 14 · 2024: 24 · 2023: 18 · 2022: 19 · 2021: 8
FWCI
1.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the Endocrine Society (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute of Child Health and Human Development
  • National Centers for Translational Research in Reproduction and Infertility (P50 HD012303, R01 HD095412, T32 HD007203)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, gut microbiota, dysbiosis, hyperandrogenism, fecal microbiota transplantation, probiotics, prebiotics, gut microbiota metabolites, obesity, PCOS etiology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review